| Item Type | Name |
|
Concept
|
Protein Kinases
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
Protein Kinase C-alpha
|
|
Concept
|
Protein Kinase Inhibitors
|
|
Concept
|
p38 Mitogen-Activated Protein Kinases
|
|
Academic Article
|
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
|
|
Academic Article
|
Protein kinase C zeta mediates epidermal growth factor-induced growth of head and neck tumor cells by regulating mitogen-activated protein kinase.
|
|
Academic Article
|
The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.
|
|
Academic Article
|
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle.
|
|
Academic Article
|
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
|
|
Academic Article
|
Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context.
|
|
Academic Article
|
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
|
|
Academic Article
|
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
|
|
Academic Article
|
mTOR: the mammalian target of replication.
|
|
Academic Article
|
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
|
|
Academic Article
|
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
|
|
Academic Article
|
New approaches to thyroid cancer.
|
|
Academic Article
|
Novel molecular targeted therapies for refractory thyroid cancer.
|
|
Academic Article
|
Treatment of squamous cell carcinoma of the head and neck in the metastatic and refractory settings: advances in chemotherapy and the emergence of small molecule epidermal growth factor receptor kinase inhibitors.
|
|
Academic Article
|
Epidermal growth factor receptor directed therapy in head and neck cancer.
|
|
Academic Article
|
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
|
|
Academic Article
|
Diarrhea associated with afatinib: an oral ErbB family blocker.
|
|
Academic Article
|
A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses.
|
|
Academic Article
|
Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
|
|
Academic Article
|
Cabozantinib in progressive medullary thyroid cancer.
|
|
Academic Article
|
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
|
|
Academic Article
|
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
|
|
Academic Article
|
Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
|
|
Academic Article
|
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
|
|
Academic Article
|
Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial.
|
|
Academic Article
|
Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine.
|
|
Academic Article
|
Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
|